EichorEICHOR
Condition: Acute Myeloblastic Leukemia Core Binding Factor Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Acute Myeloblastic Leukemia Core Binding Factor

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin
Phase 2 · 36 location(s) · National Cancer Institute (NCI) · NCT06917911The Efficacy of Allo-HSCT in ND HR-CBF-AML
Phase N/A · 1 location(s) · Ruijin Hospital · NCT06458244Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Pati
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT00801489Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Phase 2 · 12 location(s) · Children's Hospital of Soochow University · NCT06316960
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.